About the Post-Conference Report
- Our DDR analyst team have screened the data from ASH 2022 and have identified 27 abstracts (4 clinical and 23 preclinical) associated with trial or drug records on Beacon DDR.
- This post-conference report provides an analysis of the abstracts, assessed by asset, target and disease indication, followed by top-level summaries of the abstracts with links to their corresponding drug or trial page on the Beacon platform.
Find out more
This insight and data is part of the subscription to Beacon DDR.
Speak with our Team
Our dedicated Sales and Research teams can help you with questions by showing you how this insight and data is collated on Beacon
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements